Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Fujifilm Inks 1st License Deal for Avigan Patents with Chinese Pharma
June 23, 2016
- Takeda to Partner with US NPO for Joint Program to Explore Lead Compounds for TB Therapies
June 23, 2016
- Bayer Japan Revs Up Drive to Spark Behavior Change, Offers Patient Insights to Back Office Staffers
June 22, 2016
- Takao Hayakawa Tapped as New Chief of Kaketsuken
June 22, 2016
- Takeda Kicks Off PIIb Trial for Norovirus Vaccine in US
June 22, 2016
- AnGes MG Alters Global Collategene Strategy, Initial Focus Now on US
June 21, 2016
- Mitsubishi Tanabe Files US NDA for ALS Drug Edaravone, Eyes Nod by March-End
June 21, 2016
- Jannie Oosthuizen to Lead MSD Japan from July
June 21, 2016
- Cyramza Earns Lung Cancer Indication in Japan
June 21, 2016
- Co-Dio AG Makes Debut; Kipres, Ecard AGs to Hit Market Early September
June 20, 2016
- AMED-Backed Neuropathic Pain Drug Now in PI: Nippon Chemiphar, Kyushu University
June 20, 2016
- Takeda Gains Access to US Cancer Genomic Network
June 20, 2016
- Takeda’s Partnership with Tri-I TDI Now Encompasses Antibody Drug Discovery
June 20, 2016
- Novartis Seeks Chronic Hives Indication for Xolair
June 20, 2016
- Aspen Japan Looks to Expand Biz through Essential Drugs, AGs: President
June 20, 2016
- Jardiance Reduces Kidney Disease Risks Too, by 39%
June 17, 2016
- Eisai to Book 9.2 Billion Yen Gain from EA Pharma Share Acquisition
June 17, 2016
- AnGes MG to License Oral CIN Therapeutic Vaccine to Morishita Jintan
June 17, 2016
- PeptiDream’s Macrocyclic Compound Advances to Clinical Stage
June 16, 2016
- Seikagaku Licenses Lumbar Disc Herniation Drug to Ferring
June 16, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…